Scott C Flanders1, Janet Kim1, Samuel Wilson1, Jeffrey Braziunas1, Sheldon Greenfield2, John Billimek2, Stanislav Lechpammer3, Daniel W Lin4, Lawrence Karsh5, David I Quinn6, Daniel Shevrin7, Neal D Shore8, James T Symanowski9, David F Penson10. 1. Astellas Pharma, Inc., Northbrook, IL 60062, USA. 2. Health Policy Research Institute, University of California, Irvine, CA 90024, USA. 3. Medivation, Inc., which was acquired by Pfizer, Inc. in September 2016, San Francisco, CA 94105, USA. 4. Department of Urology, University of Washington, Seattle, WA 98195, USA. 5. The Urology Center of Colorado, Denver, CO 80211, USA. 6. Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA 90089, USA. 7. Medical Oncology, North Shore University Health System, Evanston, IL 60201, USA. 8. Carolina Urologic Research Center, Myrtle Beach, SC 29572, USA. 9. Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC 28025, USA. 10. Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, TN 37250, USA.
Abstract
AIM: To validate the total illness burden index for prostate cancer (TIBI-CaP) in castration-resistant prostate cancer (CRPC) patients. PATIENTS & METHODS: Baseline comorbidity scores collected using the TIBI-CaP were compared with the baseline patient-reported health-related quality of life using the SF-12v2 and FACT-P questionnaires in 302 patients enrolled in the Treatment Registry for Outcomes in CRPC Patients (TRUMPET). RESULTS: Baseline TIBI-CaP scores were negatively correlated with all baseline SF-12v2 domain/composite (p < 0.001) and FACT-P subscale/total (p < 0.020) scores. There was a significant decreasing linear trend in SF12v2 and FACT-P scores over the categories based on TIBI-CaP quartiles of comorbidity burden (from 'least' to 'severe'). CONCLUSION: The TIBI-CaP is a valid measure of comorbidity burden in patients with CRPC in the real world.
AIM: To validate the total illness burden index for prostate cancer (TIBI-CaP) in castration-resistant prostate cancer (CRPC) patients. PATIENTS & METHODS: Baseline comorbidity scores collected using the TIBI-CaP were compared with the baseline patient-reported health-related quality of life using the SF-12v2 and FACT-P questionnaires in 302 patients enrolled in the Treatment Registry for Outcomes in CRPC Patients (TRUMPET). RESULTS: Baseline TIBI-CaP scores were negatively correlated with all baseline SF-12v2 domain/composite (p < 0.001) and FACT-P subscale/total (p < 0.020) scores. There was a significant decreasing linear trend in SF12v2 and FACT-P scores over the categories based on TIBI-CaP quartiles of comorbidity burden (from 'least' to 'severe'). CONCLUSION: The TIBI-CaP is a valid measure of comorbidity burden in patients with CRPC in the real world.
Entities:
Keywords:
CRPC; TIBI-CaP; TRUMPET registry; castration-resistant prostate cancer; total illness burden index for prostate cancer
Authors: T J Daskivich; L V van de Poll-Franse; L Kwan; N Sadetsky; D M Stein; M S Litwin Journal: Prostate Cancer Prostatic Dis Date: 2010-09-14 Impact factor: 5.554
Authors: Mark S Litwin; Sheldon Greenfield; Eric P Elkin; Deborah P Lubeck; Jeanette M Broering; Sherrie H Kaplan Journal: Cancer Date: 2007-05-01 Impact factor: 6.860
Authors: N Nussbaum; D J George; A P Abernethy; C M Dolan; N Oestreicher; S Flanders; T B Dorff Journal: Prostate Cancer Prostatic Dis Date: 2016-02-02 Impact factor: 5.554
Authors: David F Penson; Daniel W Lin; Lawrence Karsh; David I Quinn; Daniel H Shevrin; Neal Shore; James T Symanowski; Bruce Brown; David Forer; Elaine K Wong; Scott C Flanders Journal: Future Oncol Date: 2016-08-16 Impact factor: 3.404